Form 4: Atea Pharmaceuticals Director Increases Equity Holdings Through RSU Conversion and New Grants

Atea Pharmaceuticals, Inc. Director Barbara Gayle Duncan reported an increase in her beneficial ownership of common stock and received new equity grants, including restricted stock units and stock options.

Summary

• Barbara Gayle Duncan, a Director of Atea Pharmaceuticals, Inc. (AVIR), reported transactions on June 20, 2025, related to her beneficial ownership.
• She acquired 29,600 shares of common stock through the conversion of previously granted restricted stock units (RSUs) at a price of $0 per share.
• Following this transaction, her direct beneficial ownership of common stock increased to 62,750 shares.
• Ms. Duncan also received a new grant of 29,600 restricted stock units (RSUs) at a price of $0 per unit, which will convert into common stock on a one-for-one basis upon vesting.
• These new RSUs are set to vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, subject to her continued service.
• Additionally, she was granted 41,200 stock options with an exercise price of $3.25 per share and an expiration date of June 19, 2035.
• These stock options will vest in twelve substantially equal monthly installments following June 20, 2025, becoming fully vested on the first anniversary of the grant date, contingent on her continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued alignment of a director's interests with shareholders through equity compensation, which is a routine and expected part of corporate governance.

Positives

• The acquisition of common stock and new equity grants align the director's interests with those of shareholders, indicating confidence in the company's future.
• The vesting schedules for both RSUs and stock options incentivize the director's continued service and long-term commitment to the company.

Future Outlook

The newly granted restricted stock units are expected to vest in a single installment on the earlier of the next annual meeting or the first anniversary of the grant date. The stock options are set to vest in twelve equal monthly installments over the first year following the grant date, with both subject to the director's continued service.

Industry Context

This filing represents a routine insider transaction, common in the biotechnology and pharmaceutical industries, where equity compensation is a standard component of executive and director remuneration to align long-term interests.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity ownership and performance incentives.
• Employees: No direct impact on general employees mentioned in this filing.
• Management: Reinforces the compensation structure for key personnel, potentially motivating long-term strategic focus.

Next Steps

• Vesting of 29,600 restricted stock units on the earlier of the next annual meeting or the first anniversary of the grant date (June 20, 2025).
• Monthly vesting of 41,200 stock options over twelve months following June 20, 2025, leading to full vesting on the first anniversary of the grant date.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Grants